NKTR
NEKTAR THERAPEUTICS
$59.38
+0.29%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders50 funds
Inst. Value$899.0M
Inst. Activity16 buys / 7 sells
Insider Activity0B / 4S
Insider Net $-$86.1K
Reddit Sentiment67° Warm
SEC Reports10
Recent Activity
Jun 11, 2026
SEC
In Q4 2025, four institutional buyers added $21.1M in NKTR positions (led by Point72 and Invesco doubling their stakes),
INST-CLUSTER — Impact 4/10
Jun 11, 2026
SEC
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) significantly in
INST-CLUSTER — Impact 3/10
May 21, 2026
SEC
Two top executives at Nektar Therapeutics (CEO Howard Robin and Chief R&D Officer Jonathan Zalevsky) sold a combined $42
CLUSTER — Impact 5/10
May 19, 2026
Insider
ROBIN HOWARD W sold 444 shares
President & CEO @ $65.51 ($29.1K)
May 19, 2026
Insider
Zalevsky Jonathan sold 199 shares
Chief R&D Officer @ $65.51 ($13.0K)
Feb 18, 2026
Insider
ROBIN HOWARD W sold 423 shares
President & CEO @ $73.00 ($30.9K)
Inst.
FMR LLC — DOUBLED
4,303,188 shares ($309.6M)
Inst.
Woodline Partners LP — DOUBLED
415,335 shares ($29.9M)
Price Targets
$153.25
+158.1% upside
Strong Buy
Current $59.38
Low $80.00
Median $150.50
High $192.00
8 analysts
$80.00
$192.00
Analyst Ratings
7Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 21, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 21, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.04 | $-2.74 — $-1.72 | 27% YoY | 4 |
| Next Q | $-0.52 ▲ +55.5% | $-3.15 — $5.30 | 72% YoY | 4 |
| Current FY | $-9.54 ▲ +4.7% | $-11.02 — $-7.62 | -10% YoY | 4 |
| Next FY | $-12.56 ▼ -11.8% | $-14.04 — $-10.18 | -32% YoY | 4 |
Latest Reports
MIXED
INST-CLUSTER
4/10
In Q4 2025, four institutional buyers added $21.1M in NKTR positions (led by Point72 and Invesco doubling their stakes),
Jun 11, 2026
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) significantly in
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $309.6M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $86.1M | — |
| TWO SIGMA INVESTMENTS, LP | $67.0M | — |
| BlackRock, Inc. | $49.8M | ADD |
| MORGAN STANLEY | $47.4M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | ROBIN HOWARD | SELL | $29.1K |
| May 19, 2026 | Zalevsky Jonathan | SELL | $13.0K |
| Feb 18, 2026 | ROBIN HOWARD | SELL | $30.9K |
| Feb 18, 2026 | Zalevsky Jonathan | SELL | $13.1K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $899.0M total value (12,497,426 shares) as of 2026-Q1. Top holders: FMR, VANGUARD, TWO. Net buying activity: 16 institutions added/increased vs 7 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 4,303,188 | $309.6M | 34.4% | DOUBLED +4155.1% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,197,055 | $86.1M | 9.6% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 930,741 | $67.0M | 7.4% | — |
| 4 | BlackRock, Inc. | 692,650 | $49.8M | 5.5% | ADD +46.7% |
| 5 | MORGAN STANLEY | 659,387 | $47.4M | 5.3% | TRIM -39.0% |
| 6 | Invesco Ltd. | 567,458 | $40.8M | 4.5% | DOUBLED +106.3% |
| 7 | CITADEL ADVISORS LLC | 513,531 | $36.9M | 4.1% | — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 433,000 | $31.2M | 3.5% | — |
| 9 | Woodline Partners LP | 415,335 | $29.9M | 3.3% | DOUBLED +299.4% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 249,090 | $17.9M | 2.0% | — |
| 11 | STATE STREET CORP | 244,727 | $17.6M | 2.0% | ADD +25.1% |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 221,100 | $15.9M | 1.8% | — |
| 13 | VANGUARD FIDUCIARY TRUST CO | 169,308 | $12.2M | 1.4% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 168,007 | $12.1M | 1.3% | ADD +39.6% |
| 15 | MARSHALL WACE, LLP | 140,588 | $10.1M | 1.1% | DOUBLED +485.2% |
| 16 | AMERIPRISE FINANCIAL INC | 136,730 | $9.8M | 1.1% | — |
| 17 | GOLDMAN SACHS GROUP INC | 126,942 | $9.1M | 1.0% | — |
| 18 | CITADEL ADVISORS LLC | 113,400 | $8.2M | 0.9% | — |
| 19 | Russell Investments Group, Ltd. | 106,248 | $7.6M | 0.9% | DOUBLED +402.5% |
| 20 | ING GROEP NV | 100,000 | $7.2M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 101,129 | 4,303,188 | +4155.1% | $309.6M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 104,000 | 415,335 | +299.4% | $29.9M | 2026-Q1 |
| STATE STREET CORP | ADD | 195,656 | 244,727 | +25.1% | $17.6M | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 120,380 | 168,007 | +39.6% | $12.1M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 24,023 | 140,588 | +485.2% | $10.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 26,092 | 58,958 | +126.0% | $4.2M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 18,821 | 55,476 | +194.8% | $4.0M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 172,881 | 41,781 | -75.8% | $3.0M | 2026-Q1 |
| Jain Global LLC | DOUBLED | 17,299 | 36,181 | +109.2% | $2.6M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 282,021 | 35,851 | -87.3% | $2.6M | 2026-Q1 |
| Legal & General Group Plc | ADD | 12,413 | 16,658 | +34.2% | $1.2M | 2026-Q1 |
| GLENMEDE TRUST CO NA | ADD | 8,590 | 13,865 | +61.4% | $997.6K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 8,629 | 13,670 | +58.4% | $983.6K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 433,419 | 13,364 | -96.9% | $961.5K | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | DOUBLED | 5,384 | 10,883 | +102.1% | $783.0K | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 8,100 | 10,729 | +32.5% | $771.1K | 2026-Q1 |
| Hudson Bay Capital Management LP | NEAR_EXIT | 59,691 | 10,332 | -82.7% | $743.4K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 1,448 | 5,949 | +310.8% | $428.0K | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 10,292 | 4,471 | -56.6% | $321.7K | 2026-Q1 |
| RHUMBLINE ADVISERS | DOUBLED | 100 | 600 | +500.0% | $43.2K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | 178 | 397 | +123.0% | $28.6K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 173,443 | 70,667 | -59.3% | $5.1K | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | EXIT | 295,716 | 0 | -100.0% | $0.00 | 2026-Q1 |
| MORGAN STANLEY | TRIM | 929,151 | 566,421 | -39.0% | $23.9M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 226,897 | 468,159 | +106.3% | $19.8M | 2025-Q4 |
2 unique insiders with 4 transactions. Net insider value: -$86.1K ($0.00 bought, $86.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | ROBIN HOWARD W | President & CEO | SELL | 444 | $65.51 | $29.1K |
| May 19, 2026 | Zalevsky Jonathan | Chief R&D Officer | SELL | 199 | $65.51 | $13.0K |
| Feb 18, 2026 | ROBIN HOWARD W | President & CEO | SELL | 423 | $73.00 | $30.9K |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | SELL | 180 | $73.00 | $13.1K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 2 mixed, 5 neutral. Avg impact: 4.5/10.
MIXED
INST-CLUSTER
4/10
In Q4 2025, four institutional buyers added $21.1M in NKTR positions (led by Point72 and Invesco dou
Jun 11, 2026
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanl
Jun 11, 2026
BEARISH
CLUSTER
5/10
Two top executives at Nektar Therapeutics (CEO Howard Robin and Chief R&D Officer Jonathan Zalevsky)
May 21, 2026
BEARISH
8-K
5/10
Nektar Therapeutics entered into an at-the-market equity distribution agreement to sell up to $150 m
May 8, 2026
NEUTRAL
8-K
4/10
Nektar Therapeutics reported Q1 2026 revenue of $10.9M (+3.8% YoY) and a net loss of $44.9M ($1.82 p
May 7, 2026
NEUTRAL
DEFA14A
3/10
Nektar Therapeutics filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, which
Apr 24, 2026
NEUTRAL
8-K
5/10
Nektar Therapeutics raised approximately $325 million through an upsized public offering of 3,532,60
Apr 23, 2026
BULLISH
424B5
7/10
Nektar Therapeutics is raising approximately $305.1 million through a public offering of 3.53 millio
Apr 23, 2026
MIXED
424B5
6/10
Nektar Therapeutics is conducting a $250 million follow-on offering of common stock and pre-funded w
Apr 20, 2026
NEUTRAL
8-K
3/10
Nektar Therapeutics disclosed it had approximately $741.7 million in cash and marketable securities
Apr 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 7 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$153.25 mean target
+158.1% upside
Strong Buy (1.30)
$80.00 Low
$192.00 High
| Metric | Value |
|---|---|
| Current Price | $59.38 |
| Target Low | $80.00 |
| Target Mean | $153.25 |
| Target Median | $150.50 |
| Target High | $192.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.04 | $-2.74 | $-1.72 | 26.7% | +0.1% | 2↑ 0↓ | $0.0B | -7.1% | 4 |
| Next Q 2026-09-30 |
$-0.52 | $-3.15 | $5.30 | 72.4% | +55.5% | — | $0.0B | -13.7% | 4 |
| Current FY 2026-12-31 |
$-9.54 | $-11.02 | $-7.62 | -10.2% | +4.7% | 1↑ 1↓ | $0.0B | -25.4% | 4 |
| Next FY 2027-12-31 |
$-12.56 | $-14.04 | $-10.18 | -31.6% | -11.8% | 0↑ 3↓ | $0.0B | -10.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.038 | |
| 7d ago | $-1.647 | -0.390 |
| 30d ago | $-2.040 | +0.002 |
| 60d ago | $-2.185 | +0.147 |
| 90d ago | $-2.920 | +0.882 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 21, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Wedbush | INITIATE | — | Neutral |
| Mar 17, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 16, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 23, 2026 | B. Riley Securities | REITERATE | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 16, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
5 mentions
3 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 16, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Lat post on CUE before it's not a penny stock
▲ 1
💬 1
⚡ 0.5
CUE is the better NKTR now
▲ 1
💬 1
⚡ 0.5
CUE is now the Better NKTR
▲ 1
💬 1
⚡ 0.5
May 13, 2026
short_interest
FTD: NKTR — 7,062 shares ($0.6M) failed to deliver
Settlement: 20260513, Price: $78.43, FTD Value: $553,872.66, NEKTAR THERAPEUTICS
May 7, 2026
earnings_calendar
NKTR Q1 2026 Earnings After Market Close — 2026-05-07
Apr 27, 2026
short_volume
Short Volume: NKTR — 63.9% short (0.4M / 0.7M)
Short: 445,176 | Exempt: 1,024 | TRF Vol: 696,992 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Mar 20, 2026
short_interest
FTD: NKTR — 17,825 shares ($1.3M) failed to deliver
Settlement: 20260320, Price: $74.84, FTD Value: $1,334,023, NEKTAR THERAPEUTICS
Mar 12, 2026
earnings_calendar
NKTR Q4 2025 Earnings After Market Close — 2026-03-12
Mar 4, 2026
earnings_calendar
NKTR Q4 2025 Earnings After Market Close — 2026-03-04
Feb 3, 2026
short_interest
FTD: NKTR — 29,789 shares ($1.1M) failed to deliver
Settlement: 20260203, Price: $38.12, FTD Value: $1,135,556.68, NEKTAR THERAPEUTICS